IYH vs VHT: Which Is the Better Pick in 2026?

Overview

IYH and VHT are both healthcare equity ETFs that track different U.S. healthcare indexes and offer low expense ratios. The key distinction is their underlying index construction: IYH follows the Dow Jones U.S. Health Care Index, which tends to concentrate on larger, more established names, while VHT tracks the MSCI U.S. Investable Market Health Care 25/50 Index, which casts a wider net across market capitalizations and applies diversification caps to limit single-stock concentration.

How they differ

VHT costs far less to own: its 0.09% expense ratio is less than one-quarter of IYH's 0.37%, a meaningful gap for buy-and-hold investors. VHT also yields more (1.23% versus 0.90%), though both offer modest dividend streams relative to the broader market. The bigger structural difference lies in index philosophy. The MSCI index underlying VHT explicitly limits any single position to no more than 50% of its sector weight and no single holding above 5% of the fund's total assets, which tends to produce a more dispersed portfolio than the Dow Jones methodology; this matters because healthcare includes both mega-cap pharma giants and mid-cap medtech firms. VHT also commands significantly larger assets—$19.4B versus $3.88B—which typically means tighter spreads and more reliable pricing liquidity.

Who each is best for

IYH: Fits investors seeking concentrated exposure to blue-chip healthcare names and who prioritize the Dow Jones methodology's focus on established, liquid companies over broad market representation.

VHT: Designed for investors who want diversified healthcare exposure across the full investable market and value cost efficiency, especially those planning long-term accumulation where the 0.29% expense ratio difference compounds over decades.

Key risks to know

• Index concentration: IYH's underlying index may concentrate more heavily in mega-cap pharmaceutical and medical device firms; verify whether your existing holdings already overlap with its top positions before adding exposure.

• Sector cyclicality: Both ETFs are entirely dependent on healthcare sector performance—regulatory changes, drug pricing reform, or shifts in reimbursement models can depress valuations across the entire sector.

• Beta divergence: While both betas are moderate (0.52 for IYH, 0.57 for VHT), they measure sensitivity to different benchmark movements; IYH's lower beta reflects the Dow Jones index's large-cap tilt, but this does not mean lower volatility in healthcare-specific downturns.

• Dividend sustainability: Both funds' yields are modest and should not be assumed to grow; healthcare companies prioritize R&D spending and dividends can be cut or suspended if drug pipelines underperform.

Bottom line

If you prioritize cost efficiency and want broad healthcare diversification with minimal constraint, VHT's 0.09% expense ratio and diversification caps stand out; if you prefer a more concentrated, large-cap healthcare portfolio and already track the Dow Jones elsewhere, IYH's approach may align better with your indexing strategy. Past performance doesn't predict future results.